Testing a new staging system for cutaneous melanoma proposed by the American Joint Committee on Cancer.
The American Joint Committee on Cancer (AJCC) recently proposed a new staging system for cutaneous melanoma. We tested its practicability and its prognostic value was compared with the currently used TNM classification. The data of 1976 melanoma patients were used for the testing. 1218 patients (61.6%) could be assigned to the proposed pT classification, 136 patients (90.1%) with lymph node metastases and/or in-transit metastases to the proposed pN classification and all 14 patients with distant metastases to the proposed pM classification. Proposed pathological staging was possible for 971 patients (49%). The number of pT1 patients (399 versus 230) and stage I patients (544 versus 393) was distinctly higher in the proposed classification. In proposed stage II and III groups, subgroups with different prognosis could be identified. The new staging system includes more detailed information on clinical and pathohistological findings. Nevertheless, it is practicable and enables more patients with excellent prognosis to be identified.
Merkel
S
S
Department of Surgery, University of Erlangen, Krankenhausstr. 12, D-91054, Erlangen, Germany. susanne.merkel@chir.imed.uni-erlangen.de
Meyer
T
T
Papadopoulos
T
T
Schuler
G
G
Göhl
J
J
Hohenberger
W
W
Hermanek
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D012878:Skin Neoplasms / Q000473:pathology*; D016019:Survival Analysis